scholarly journals Effect of Carotid Artery Morphological Variations on Cognitive Function

2018 ◽  
Vol 2018 ◽  
pp. 1-6 ◽  
Author(s):  
Lin Chen ◽  
Jialu Huang ◽  
Suxia Wang ◽  
Hong Ran ◽  
Lan Wen ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Carotid Artery ◽  
Verbal Fluency ◽  
Morphological Variations ◽  
Type Group ◽  
Significant Difference ◽  
Positive Rate ◽  
Digital Subtract Angiography ◽  
State Scale

Background. Carotid artery morphological variations (CAMV) are common variations on medical imaging; the effects of CAMV on cognition were still unknown. This study is aimed at investigating whether carotid artery morphological variations (CAMV) cause cognitive impairment. Methods. Hospitalized patients from March 2017 to October 2017 who underwent digital subtract angiography (DSA) were divided into non-CAMV group, T-type group, K-type group, and C-type group according to their carotid artery morphology. Cognitive function in each group was evaluated with the Mini-Mental State Scale (MMSE), the Montreal Cognitive Assessment (MoCA), the Verbal Fluency Test (VFT), and the Digital Span Test (DST). Results. A total of 96 patients were included in the study (32 in non-CAMV group, 34 in T-type group, 30 in K-type group, and none in C-group). The positive rate of MMSE in the non-CAMV group, the T-type group, and the K-type group was 15.6%, 14.7%, and 20.0%, respectively, with no statistical difference in the three groups (p=0.836). The positive rate of MoCA in the K-type group was significantly higher than that in the non-CAMV and the T-type groups (p<0.001), but there was no significant difference between the non-CAMV group and the T-type group (p=0.826). The VFT, DST forward score, and backward score in the K-type group were significantly lower than those in the non-CAMV and the T-type groups (p<0.001). Conclusions. K-type CAMV may cause cognitive impairment, and MoCA is superior to MMSE in identifying mild cognitive impairment caused by CAMV.

scholarly journals Saffron for mild cognitive impairment and dementia: a systematic review and meta-analysis of randomised clinical trials

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Zahra Ayati ◽  
Guoyan Yang ◽  
Mohammad Hossein Ayati ◽  
Seyed Ahmad Emami ◽  
Dennis Chang
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Clinical Trials ◽  
Cognitive Impairment ◽  
Mild Cognitive Impairment ◽  
Cognitive Function ◽  
Daily Living ◽  
Randomised Clinical Trials ◽  
Disease Assessment ◽  
Significant Difference

Abstract Background Saffron (stigma of Crocus sativus L.) from Iridaceae family is a well-known traditional herbal medicine that has been used for hundreds of years to treat several diseases such as depressive mood, cancer and cardiovascular disorders. Recently, anti-dementia property of saffron has been indicated. However, the effects of saffron for the management of dementia remain controversial. The aim of the present study is to explore the effectiveness and safety of saffron in treating mild cognitive impairment and dementia. Methods An electronic database search of some major English and Chinese databases was conducted until 31st May 2019 to identify relevant randomised clinical trials (RCT). The primary outcome was cognitive function and the secondary outcomes included daily living function, global clinical assessment, quality of life (QoL), psychiatric assessment and safety. Rev-Man 5.3 software was applied to perform the meta-analyses. Results A total of four RCTs were included in this review. The analysis revealed that saffron significantly improves cognitive function measured by the Alzheimer’s Disease Assessment Scale-cognitive subscale (ADAS-cog) and Clinical Dementia Rating Scale-Sums of Boxes (CDR-SB), compared to placebo groups. In addition, there was no significant difference between saffron and conventional medicine, as measured by cognitive scales such as ADAS-cog and CDR-SB. Saffron improved daily living function, but the changes were not statistically significant. No serious adverse events were reported in the included studies. Conclusions Saffron may have the potential to improve cognitive function and activities of daily living in patients with Alzheimer’s disease and mild cognitive impairment (MCI). However, due to limited high-quality studies there is insufficient evidence to make any recommendations for clinical use. Further clinical trials on larger sample sizes are warranted to shed more light on its efficacy and safety.

scholarly journals Cognitive impairment in a Brazilian sample of patients with bipolar disorder

2008 ◽  
Vol 30 (3) ◽  
pp. 209-214 ◽  
Author(s):  
Júlia J Schneider ◽  
Rafael H Candiago ◽  
Adriane R Rosa ◽  
Keila M Ceresér ◽  
Flávio Kapczinski
Keyword(s):  
Bipolar Disorder ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Cognitive Deficits ◽  
Healthy Subjects ◽  
Neurocognitive Deficits ◽  
Brazilian Sample ◽  
Bipolar Mood Disorder ◽  
Significant Difference ◽  
Sample Method

OBJECTIVE: Persistent neurocognitive deficits have been described in bipolar mood disorder. As far as we are aware, no study have examined whether the cognitive impairment is presented in the same way in a Brazilian sample. METHOD: Cognitive function of 66 patients with bipolar disorder (32 with depressive symptoms and 34 euthymic) and 28 healthy subjects was examined using a complete cognitive battery. RESULTS: Patients with bipolar disorder presented a significantly poorer performance in eight of the 12 subtests when compared to healthy subjects. There was no significant difference between the subgroups of patients. These patients showed impairment in both verbal and non-verbal cognitive function. CONCLUSION: Cognitive impairment was found in both groups of patients with bipolar disorder. The findings described here suggest an overall impairment of cognitive function, independent of mood symptoms. This is in line with data showing that cognitive deficits may be a persistent characteristic of bipolar disorder.

scholarly journals Nithsdale Schizophrenia Surveys 20

2000 ◽  
Vol 177 (4) ◽  
pp. 348-353 ◽  
Author(s):  
C. Kelly ◽  
V. Sharkey ◽  
G. Morrison ◽  
J. Allardyce ◽  
R. G. McCreadie
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Cognitive Deficits ◽  
Verbal Fluency ◽  
Mini Mental State Examination ◽  
Community Based ◽  
Adult Reading ◽  
The Mean ◽  
National Adult Reading Test ◽  
State Examination

BackgroundCognitive deficits are a core aspect of schizophrenia but there has been no study of cognitive function in a catchment-area-based population of patients with schizophrenia.AimsTo assess cognitive function in a population of patients with schizophrenia, and relate it to community functioning.MethodAll patients with schizophrenia in Nithsdale, south-west Scotland, were identified (n=182). Measures of assessment were: National Adult Reading Test (NART), Mini-Mental State Examination (MMSE), Rivermead Behavioural Memory Test (RBMT), Executive Interview (EXIT), FAS Verbal Fluency and Health of the Nation Outcome Scales (HoNOS).ResultsWe assessed 138 patients, mean age 48 years (standard deviation (s.d.) 15). Only 14% were in-patients. The mean premorbid IQ as assessed by NART was 98 (s.d. 14); 15% of patients had significant global cognitive impairment (MMSE); 81% had impaired memory (RBMT); 25% had executive dyscontrol (EXIT); and 49% had impaired verbal fluency (FAS). Scores on the functional impairment sub-scale of HoNOS correlated with all measures of cognitive impairment.ConclusionsCognitive dysfunction is pervasive in a community-based population of patients with schizophrenia.

scholarly journals Effect of hemorrhagic cerebrospinal fluid drainage on cognitive function after intracranial aneurysm clipping

2019 ◽  
Vol 5 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Chaoqun Lin ◽  
Lukui Chen
Keyword(s):  
Cerebrospinal Fluid ◽  
Cognitive Impairment ◽  
Subarachnoid Hemorrhage ◽  
Cognitive Function ◽  
Lumbar Puncture ◽  
Aneurysmal Subarachnoid Hemorrhage ◽  
Cerebrospinal Fluid Drainage ◽  
Aneurysm Clipping ◽  
Significant Difference ◽  
Drainage Group

Objective: The effects of repeated lumbar puncture and continuous lumbar cistern drainage on the cognitive function of patients with aneurysmal subarachnoid hemorrhage were compared and analyzed. Methods: Retrospective analysis was performed on 59 patients with aneurysmal subarachnoid hemorrhage treated at our Neurosurgery Department between October 2017 and October 2018. According to the hemorrhagic cerebrospinal fluid drainage mode after aneurysm clipping, the patients were divided into the following two groups: the repeated lumbar puncture drainage (Group A, n = 28) and continuous lumbar cistern drainage (Group B, n = 31). Before and 1 month after surgery, the cognitive function of the patients was scored using the Montreal Cognitive Assessment Scale. Scores of 27~30 were defined as normal, and scores of < 27 as cognitive impairment. Results: The incidences of cognitive impairment were 46% (13/28) and 32% (10/31) for Groups A and B, respectively, before surgery, but the difference was not significant ( P > 0.05). The incidences of cognitive impairment were 35% (10/28) and 12% (4/31) for Groups A and B, respectively, at 1 month after surgery, with significant difference ( P < 0.05). Conclusion: Compared with repeated lumbar puncture, continuous lumbar cistern drainage for aneurysmal subarachnoid hemorrhage significantly reduced the incidence of cognitive impairment after aneurysm clipping.

Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9099-9099
Author(s):  
J. L. Vardy ◽  
S. Rourke ◽  
G. R. Pond ◽  
J. Galica ◽  
A. Park ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Healthy Volunteers ◽  
Clotting Factors ◽  
Related Factors ◽  
Post Surgery ◽  
Significant Difference ◽  
Cytokine Levels ◽  
Group A ◽  
Group B

9099 Background: There is growing evidence that fatigue and cognitive dysfunction can affect cancer survivors. Here we evaluated these symptoms in patients with CRC in a longitudinal prospective study. Methods: Patients with localized CRC were evaluated for cognitive function and fatigue at baseline (mean 8 weeks post-surgery or before neoadjuvant therapy), 6 & 12 months. Group A (Stage III/high risk II) received chemotherapy (CT) and group B (Stage I/II) received no CT. Pts had neuropsychological (NP) assessment with traditional tests and CANTAB, a computerized NP battery. They completed concurrent questionnaires for fatigue & QOL (FACT-F), anxiety/depression (GHQ), and perception of cognitive function (FACT-COG). Blood tests evaluated cytokine levels, blood clotting factors, sex hormones and apolipoprotein genotyping as potential causal factors. Primary endpoints were cognitive function (traditional NP tests) and fatigue. Associations between test results, demographic and disease-related factors were sought. Results: Baseline data are available for 182 pts: 127 group A, and 55 group B, with follow-up at 6 and 12 months for 71 and 39 pts. Mean age was 57 years and 62% were male. At baseline (pre CT): 30% had cognitive impairment on traditional NP tests & 20% on CANTAB; 25% reported moderate fatigue and 10% extreme fatigue. At 6 months there was no significant difference on objective NP testing between the groups or in perceived cognitive impairment (median FACT- COG 82 vs 88, p=0.34). CT pts had more fatigue (median FACT-F 75 vs 91, p<0.001). At 12 months CT pts tend to have more cognitive impairment on traditional NP tests (26% vs 0%, p=.09), more perceived cognitive impairment (13.5% vs 0%, p=.57) & greater fatigue (16% vs 0%). Cytokine levels were elevated in all groups at all time points compared to healthy volunteers. There was a trend to higher cytokine levels with greater fatigue and worse cognitive impairment. Fatigue, QOL and anxiety and depression were highly correlated. Conclusions: Cognitive impairment is present in some pts prior to CT and there is a trend for CT pts to have worse cognitive impairment at 12 but not at 6 months. Fatigue is associated with CT. Cytokine levels remained elevated in all groups compared to healthy volunteers. No significant financial relationships to disclose.

scholarly journals Changes in Cognition, Depression and Quality of Life after Carotid Stenosis Treatment

2019 ◽  
Vol 16 (1) ◽  
pp. 47-62 ◽  
Author(s):  
Elina Pucite ◽  
Ildze Krievina ◽  
Evija Miglane ◽  
Renars Erts ◽  
Dainis Krievins ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Depressive Symptoms ◽  
Cognitive Function ◽  
Carotid Artery ◽  
Carotid Stenosis ◽  
Cognitive Performance ◽  
Best Medical Treatment ◽  
Significant Difference ◽  
Kendall’S W

Background:Although several studies have evaluated the change of cognitive performance after severe carotid artery stenosis, the results still remain elusive. The objective of this study was to assess changes in cognitive function, depressive symptoms and Health Related Quality of Life (HRQoL) after carotid stenosis revascularisation and Best Medical Treatment (BMT).Methods:Study involved 213 patients with ≥70% carotid stenosis who underwent assessment of cognitive function using Montreal Cognitive Assessment scale (MoCA), depressive symptoms - using Patient Health Questionnaire-9 (PHQ-9) and HRQoL - using Medical Outcome Survey Short Form version 2 (SF-36v2). The assessment was performed before and at 6 and 12 months followup periods in patients who had Carotid Endarterectomy (CEA), Carotid Artery Stenting (CAS) or received BMT only.Results:Improvement in the total MoCA scores was observed after 6 and 12 months (p<0.001, Kendall's W=0.28) in the CEA group. In the CAS group - after 12 months (p=0.01, Kendall's W=0.261) whereas in the BMT group - no significant changes (p=0.295, Kendall's W=0.081) were observed. Reduction of depressive symptoms was not found in any of the study groups. Comparing mean SF-36v2 scores in the CEA group, there was no significant difference in any of 10 subscales. Likewise in the CAS group - no significant difference in 9 of 10 subscales (p=0.028, η2=0.343) was observed. Three subscales worsened in the BMT group during the 1-year follow-up period.Conclusion:Patients with severe carotid stenosis who underwent revascularisation enhanced their cognitive performance without exerting significant change of depressive symptoms. Preoperative HRQoL may be maintained for at least one year in the CEA group.

scholarly journals Cognitive function and carotid stenosis: review of the literature

2012 ◽  
Vol 6 (3) ◽  
pp. 127-130 ◽  
Author(s):  
Aurélio Pimenta Dutra
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Carotid Artery ◽  
Carotid Stenosis ◽  
Carotid Artery Stenosis ◽  
Internal Carotid ◽  
Artery Stenosis ◽  
Asymptomatic Carotid ◽  
Asymptomatic Carotid Artery Stenosis ◽  
The Relationship

ABSTRACT Stroke is a known cause of cognitive impairment but the relationship between asymptomatic carotid artery stenosis and cognitive function is not clear. The main risk factors for vascular disease are also related to carotid stenosis and cognitive impairment. The association of high-grade stenosis of the internal carotid artery with cognitive impairment is related to silent embolization and hypoperfusion, but it may also be present without evidence of infarction on magnetic resonance imaging. Carotid stenosis treatment may lead to a decline in cognitive function due to complications related to the procedures (endarterectomy or stenting). On the other hand, reperfusion may improve cognitive impairment. The best treatment choice is unclear, considering possible deterioration of cognitive function related to carotid artery stenosis. There is insufficient evidence to consider cognitive impairment an important factor in determining the therapy for carotid stenosis.

scholarly journals Right Frontoinsular Cortex: A Potential Imaging Biomarker to Evaluate T2DM-Induced Cognitive Impairment

2021 ◽  
Vol 13 ◽  
Author(s):  
Dongsheng Zhang ◽  
Yumeng Lei ◽  
Jie Gao ◽  
Fei Qi ◽  
Xuejiao Yan ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Cognitive Function ◽  
Cognitive Dysfunction ◽  
Inferior Frontal Gyrus ◽  
Brain Network ◽  
Imaging Biomarker ◽  
Linear Processes ◽  
Significant Difference ◽  
Normal Cognitive Function ◽  
The Right

Cognitive impairment in type 2 diabetes mellitus (T2DM) is associated with functional and structural abnormalities in the intrinsic brain network. The salience network (SN) is a neurocognitive network that maintains normal cognitive function, but it has received little attention in T2DM. We explored SN changes in patients with T2DM with normal cognitive function (DMCN) and in patients with T2DM with mild cognitive impairment (DMCI). Sixty-five T2DM patients and 31 healthy controls (HCs) underwent a neuropsychological assessment, independent component analysis (ICA), and voxel-based morphometry (VBM) analysis. The ICA extracted the SN for VBM to compare SN functional connectivity (FC) and gray matter (GM) volume (GMV) between groups. A correlation analysis examined the relationship between abnormal FC and GMV and clinical/cognitive variables. Compared with HCs, DMCN patients demonstrated increased FC in the left frontoinsular cortex (FIC), right anterior insula, and putamen, while DMCI patients demonstrated decreased right middle/inferior frontal gyrus FC. Compared with DMCN patients, DMCI patients showed decreased right FIC FC. There was no significant difference in SN GMV in DMCN and DMCI patients compared with HCs. FIC GMV was decreased in the DMCI patients compared with DMCN patients. In addition, right FIC FC and SN GMV positively correlated with Montreal Cognitive Assessment and Mini-Mental State Examination (MMSE) scores. These findings indicate that changes in SN FC, and GMV are complex non-linear processes accompanied by increased cognitive dysfunction in patients with T2DM. The right FIC may be a useful imaging biomarker for supplementary assessment of early cognitive dysfunction in patients with T2DM.

scholarly journals COMPARISON OF COGNITIVE FUNCTION BETWEEN FIRST ISCHEMIC STROKE AND RECURRENT ISCHEMIC STROKE PATIENTS

2022 ◽  
Vol 8 (1) ◽  
pp. 30-34
Author(s):  
Fildza Intan Rizkia ◽  
Chandra Calista ◽  
Suryani Gunadharma ◽  
Asep Nugraha Hermawan ◽  
Lisda Amalia ◽  
...  
Keyword(s):  
Ischemic Stroke ◽  
Cognitive Impairment ◽  
Cognitive Function ◽  
Recurrent Stroke ◽  
Demographic Data ◽  
P Value ◽  
Stroke Patients ◽  
Cross Sectional ◽  
Significant Difference ◽  
Stroke Group

Background: Cognitive impairment is a common condition that may affect up to 50% of stroke patients. Post stroke cognitive impairment is associated with reduced quality of life, which may increase the number of dependency. Recurrent stroke may happen in approximately 25% patients and they have higher rates of cognitive impairment. Objective: The aim of this study is to examine the comparison of cognitive function between first ischemic stroke and recurrent ischemic stroke patients in Hasan Sadikin Hospital, Bandung. Methods: This study is a retrospective, cross-sectional study using the data recruited between the year 2012 - 2016 at the Department of Neurology at the Hasan Sadikin Hospital Bandung. The data collected in this study were demographic data, including age, level of education, and residence, and the clinical data as well. Cognitive function was assessed using Mini-Mental State Examination (MMSE). The comparison between the cognitive function between both groups were analyzed using the Mann-Whitney U test. Results: There were 428 subjects eligible for this study, with 207 subjects categorized as first ischemic stroke group and 221 subjects categorized as recurrent ischemic stroke group. There was a statistically significant difference in MMSE scores between the first ischemic stroke patients (24.90 ± 4.64) and recurrent ischemic stroke patients (22.85 ± 4.64 ) with a p value of 0.002. Conclusion: Recurrent ischemic stroke patients had lower MMSE scores than the first ischemic stroke patients. Clinicians should be more aware in detecting early cognitive impairment in stroke patients and in preventing the incidence of recurrent stroke.

Sign in / Sign up

Export Citation Format

Share Document